Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Jul 30:12:721146.
doi: 10.3389/fneur.2021.721146. eCollection 2021.

Vaccine Induced Immune Thrombotic Thrombocytopenia Causing a Severe Form of Cerebral Venous Thrombosis With High Fatality Rate: A Case Series

Affiliations
Case Reports

Vaccine Induced Immune Thrombotic Thrombocytopenia Causing a Severe Form of Cerebral Venous Thrombosis With High Fatality Rate: A Case Series

Markus Wiedmann et al. Front Neurol. .

Abstract

During a 2-week period, we have encountered five cases presenting with the combination of cerebral venous thrombosis (CVT), intracerebral hemorrhage and thrombocytopenia. A clinical hallmark was the rapid and severe progression of disease in spite of maximum treatment efforts, resulting in fatal outcome in for 4 out of 5 patients. All cases had received ChAdOx1 nCov-19 vaccine 1-2 weeks earlier and developed a characteristic syndrome thereafter. The rapid progressive clinical course and high fatality rate of CVT in combination with thrombocytopenia in such a cluster and in otherwise healthy adults is a recent phenomenon. Cerebral autopsy findings were those of venous hemorrhagic infarctions and thrombi in dural venous sinuses, including thrombus material apparently rich in thrombocytes, leukocytes and fibrin. Vessel walls were free of inflammation. Extra-cerebral manifestations included leech-like thrombi in large veins, fibrin clots in small venules and scattered hemorrhages on skin and membranes. CVT with thrombocytopenia after adenovirus vectored COVID-19 vaccination is a new clinical syndrome that needs to be recognized by clinicians, is challenging to treat and seems associated with a high mortality rate.

Keywords: COVID-19; COVID-19 vaccine AstraZeneca; ChAdOx1 nCoV-19; SARS-CoV-2 virus; cerebral venous thrombosis; complication; sinus vein thrombosis; thrombocytopenia.

PubMed Disclaimer

Conflict of interest statement

MW research grants from the South-Eastern Norway Regional Health Authority (grant number 2014060), ownership of stock Biontech/Pfizer. IS reports that her spouse is the CFO in ArcticZymes Technologies. CL personal fees from Bristol Myers Squibb. PH personal fees from Takeda, grants and personal fees from SOBI, grants and personal fees from Bayer, grants and personal fees from Pfizer, personal fees from Roche, personal fees from Octapharma, personal fees from NovoNordisk, personal fees from CSL, personal fees from BMS. AA personal fees from Bayer, personal fees from Boehringer Ingelheim, personal fees from Roche, personal fees from Allergan, personal fees from Novartis, personal fees from Teva. NS personal fees from BMS/Pfizer, personal fees from Bayer. KS personal fees from Bayer. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Axial and coronal CT from patient 1 (A), 2 (B) and 5 (C). These patients presented with large parenchymal hemorrhages. Note the fluid-fluid levels [arrows, (A,C)], the subarachnoid hemorrhage [arrowheads, (A,C)] and the heterogeneous appearance of all hematomas.
Figure 2
Figure 2
MRI of patient 4 (upper row) and patient 2 (lower row), axial T2-weighted images (A,D), axial T1-weighted images (B,E) and contrast-enhanced axial T1-weighted images (C,F). A complex signal in hematomas of venous infarctions in the right cerebellar hemisphere (patient 4) and left temporal lobe (patient 2) is seen. Multiple fluid-fluid levels (arrows) and sedimentation indicate not fully coagulated blood. Multifocal areas of high signal intensity within the hematoma represents extravasated contrast agent [arrow heads, (F)]. An acute thrombus in the right transverse and sigmoid sinus [open arrow, (C)] cause a well-defined filling defect on the contrast-enhanced T1-MPRAGE. The round lesion with low signal intensity on T2-weighted image [thick arrow, (D)] was tubular on consecutive slices, showed lack of contrast enhancement and is compatible with a cortical vein thrombosis.
Figure 3
Figure 3
MRI, CT, and CT venography of patient 3. Thrombosis in a cortical vein (thin arrows) is possible to spot with high signal intensity on axial FLAIR (A) and filling defect on contrast enhanced axial T1-MPRAGE (B). Corresponding temporo-occipital hemorrhage (open arrow), cerebellar hemorrhage and high attenuation from thrombus in transverse and sigmoid sinuses can be seen on coronal CT (E). 3D phase-contrast MR venography demonstrates loss of flow signal in left transverse and sigmoid sinus (D). The thrombus in sigmoid sinus (thick arrows) is also evident on contrast enhanced axial T1-MPRAGE (C) and CT venography (F).
Figure 4
Figure 4
Autopsy findings in patient 5: (A) Coronal section of the formalin-fixed brain. Extensive hemorrhagic infarction (red arrows) in both hemispheres and major hemorrhage with communication to the brain surface and ventricular system. (B) Posterior sagittal sinus with a white thrombus. (C) Formalin fixed dura. Sagittal sinus with thrombus formation (arrow). (D) Cross-section of formalin fixed right transverse sinus with white thrombus (arrow).

References

    1. Norwegian Institute of Public Health . COVID 19 Ukerapport — uke 15 A. (2021). Available online at: https://www.fhi.no/contentassets/8a971e7b0a3c4a06bdbf381ab52e6157/vedleg... (accessed April 27, 2021).
    1. Schultz NH, Sørvoll IH, Michelsen AE, Munthe LA, Lund-Johansen F, Ahlen MT, et al. . Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med. (2021) 384:2124–30. 10.1056/NEJMoa2104882 - DOI - PMC - PubMed
    1. Saposnik G, Barinagarrementeria F, Brown RD, Jr, Bushnell CD, Cucchiara B, Cushman M, et al. . Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American heart association/American stroke association. Stroke. (2011) 42:1158–92. 10.1161/STR.0b013e31820a8364 - DOI - PubMed
    1. Afifi K, Bellanger G, Buyck PJ, Zuurbier SM, Esperon CG, Barboza MA, et al. . Features of intracranial hemorrhage in cerebral venous thrombosis. J Neurol. (2020) 267:3292–8. 10.1007/s00415-020-10008-0 - DOI - PubMed
    1. Panda S, Prashantha DK, Shankar SR, Nagaraja D. Localized convexity subarachnoid haemorrhage–a sign of early cerebral venous sinus thrombosis. Eur J Neurol. (2010) 17:1249–58. 10.1111/j.1468-1331.2010.03001.x - DOI - PubMed

Publication types